Loading stock…

United Therapeutics Corporation (UTHR) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

United Therapeutics Corporation

UTHRMarket cap $23BPrice $545.0

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops therapies for pulmonary hypertension and organ failure, and is now literally growing transplantable pig organs to end the human donor shortage. Its Tyvaso franchise alone generates over a billion dollars a year in revenue.

In Bastion Portfolios?

52W Return+26%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+18%9

Revenue Forecast

Rev CAGR (1y)-1%2

Rev CAGR (3y)+8%6

Rev CAGR (5y)+13%8

Earnings Forecast

EPS Growth Y+1-5%3

EPS Growth Y+2+12%7

EPS Growth Y+3+23%8

Quality

Margins

EBIT Margin45%10

Net Income Margin42%10

Free Cash Flow Margin35%9

Debt

Net Debt/EBITDA-2.510

Efficiency

ROE19%8

ROA17%10

Earnings Stability88

GEAR+VERY STRONG96

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)175

P/E Ratio (Forward 3y)145

P/BV3.74

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd136

Yield

Free Cash Flow Yield4.7%6

Dividend Yieldna–

Momentum

Short term

1 month return+9%10

3 month return-2%6

YTD return+12%7

Mid term

Price vs 52wHigh89%8

1 year return+21%7

Long term

3 year return+133%8

5 year return+179%9

Risk Shield

Price Risk

Beta0.57

Volatility34%6

Free Cash Flow

Free Cash Flow Margin35%9

Free Cash Flow Yield4.7%6

Quality

ROCE20%9

Earnings Stability88

Net Debt/EBITDA-2.510

02Growth

Is it actually growing, and how fast?

UTHRUnited Therapeutics

Revenue FY25$3.2B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-5%3

EPS growth, FY27E+12%7

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, in line with the market.5/10

Revenue grew 18%/yr over the last 3 years; forecasts see it cooling to 8%/yr.

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 8%/yr). One year dips: EPS falls 5% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG86 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return-2%6

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+21%7

3-year return+133%8

5-year return+179%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +133% over three years and +179% over five, ahead of 80% of the market.

It's up 21% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+9%) and so far this year (+12%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on United Therapeutics Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

UTHRUnited Therapeutics

Revenue FY25$3.2B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-5%3

EPS growth, FY27E+12%7

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, in line with the market.5/10

Revenue grew 18%/yr over the last 3 years; forecasts see it cooling to 8%/yr.

Earnings are set to grow in step with sales (EPS about 12%/yr vs revenue 8%/yr). One year dips: EPS falls 5% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG86 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return-2%6

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high89%8

1-year return+21%7

3-year return+133%8

5-year return+179%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +133% over three years and +179% over five, ahead of 80% of the market.

It's up 21% over the past year, but 11% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+9%) and so far this year (+12%).

WATCH

Returns sit at the market level over three months (-2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on United Therapeutics Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community